Home › Mental Disorders › NCT06878859

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Aged ≥ 18 years
* Resides in the United States
* Able to read and understand English and willing to provide informed consent/comply with the study protocol
* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
* Current elevated anhedonia, as indicated by the PHQ-9
* Interest in receiving treatment for their cannabis use and depression
* Meet criteria for current MDD and CUD per the DSM-5

Exclusion Criteria:

* History of a psychotic disorder or bipolar disorder type I/II
* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
* Current psychotherapy engagement
* Changes in psychotropic medication within six weeks of the start of study

About the study

The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.

What is being tested

• Amplification of Positivity - Cannabis Use (AMP-C) (behavioral)

Sponsor: Massachusetts General Hospital · Participants: 80 · Started: Feb 23, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT06878859

Locations in the U.S.

Conditions

• Mental Disorders

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.